Premium
Use of IVIg to identify potential miRNA targets for allograft rejection and GvHD therapy
Author(s) -
Padet Lauriane,
Loubaki Lionel,
Bazin Renée
Publication year - 2015
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12549
Subject(s) - medicine , microrna , cd80 , immunology , transplantation , graft versus host disease , cytokine , in vitro , gene , cd40 , biology , cytotoxic t cell , biochemistry
Allograft rejection ( AR ) and graft‐versus‐host disease (Gv HD ) are serious complications following transplantation. Micro‐ RNA s (mi RNA s) have recently been identified as key players in the regulation of these disorders. Because intravenous immunoglobulin ( IVI g) has shown therapeutic potential for the prophylaxis and post‐transplant reduction of AR and Gv HD , we hypothesized that the effect of IVI g could result from the modulation of specific mi RNA expression. To identify such mi RNA , we performed mixed lymphocyte reactions ( MLR s) as an in vitro model of AR and Gv HD , with or without IVI g. We herein show that IVI g strongly inhibits the MLR s. This inhibition is associated with a modulation in the expression of mi RNA s implicated in the regulation of pro‐inflammatory cytokine ( IL ‐2, IL ‐6, IFN ‐γ) and costimulatory molecule ( CD 80) expression. We propose that these identified mi RNA s could represent potential therapeutic targets for the prevention and therapy of AR and Gv HD .